When	it	approved	Avonex	in	May	,	the	FDA	said	both	Biogen	's	product	and	Betaseron	were	developed	under	the	incentives	of	the	Ophran	Drug	Act	which	provides	seven	years	of	marketing	exclusivity	for	products	that	treat	rare	diseases	.